An estimated half of the world’s population who need access to Rh Immune Globulin to prevent D alloimmunization, do not receive it. This means that 3 million women annually, do not receive prevention, a large proportion of which are located in Sub-Saharan Africa and South Asia. In Sub-Saharan Africa, there is no reliable or affordable access to RhIg, as well as little to no treatment of HDFN, leading to devastating consequences for families.
Rose, our AHF ambassador to Kenya is now leading work on the ground in Africa; providing vital education and resources to women about prevention, diagnosis and treatment. While ideal care is difficult to find in Kenya, we are encouraged to see many recent improvements for patients with Rh disease. We have established relationships with several doctors who are working hard to support patients, and we can help connect patients with these doctors if high risk care is needed.
